| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
2 Mental Health Research Institute, 1 Department of Pediatrics, and 3 Department of Psychiatry, University of Michigan, Ann Arbor, Michigan 48109-0720
Dexamethasone is commonly used to lessen the morbidity of chronic lung disease in premature infants, but little is known regarding neurological consequences of its prolonged use. To study neurological effects of dexamethasone, we have developed a rat model in which newborn pups are exposed to tapering doses of dexamethasone at a time corresponding neurodevelopmentally to human exposure in the neonatal intensive care unit. On postnatal day (PD) 2, litters were divided into three groups: 1) handled controls, 2) saline-injected animals, and 3) animals injected with tapering doses of intramuscular dexamethasone between PD 3 and 6. Somatic growth and brain weight were decreased in dexamethasone-treated animals. Dexamethasone-treated animals demonstrated delays in gross neurological development on PD 7 and 14 but not PD 20. In late adolescence (PD 33), dexamethasone-treated animals were less active in light and dark environments, while demonstrating a blunted serum corticosterone response to a novel stress. The dissociation between behavioral and hormonal stress responsiveness suggests that neonatal dexamethasone exposure permanently alters central nervous system function, particularly within the neuroendocrine stress axis. This may lead to increased risk for learning impairment and maladaptive responses to the environment.
steroids; prematurity; brain; corticosterone; limbic-hypothalamic-pituitary-adrenal axis
This article has been cited by other articles:
|
|
 |
|
  R. Karemaker, A. Kavelaars, M. ter Wolbeek, M. Tersteeg-Kamperman, W. Baerts, S. Veen, J. F. Samsom, G. H. A. Visser, F. van Bel, and C. J. Heijnen Neonatal Dexamethasone Treatment for Chronic Lung Disease of Prematurity Alters the Hypothalamus-Pituitary-Adrenal Axis and Immune System Activity at School Age Pediatrics, April 1, 2008; 121(4): e870 - e878. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Bal, W. B. de Vries, M. F. M. van Oosterhout, J. Baan, E. E. van der Wall, F. van Bel, and P. Steendijk Long-term cardiovascular effects of neonatal dexamethasone treatment: hemodynamic follow-up by left ventricular pressure-volume loops in rats J Appl Physiol, February 1, 2008; 104(2): 446 - 450. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. C Eichenwald and A. R Stark Are postnatal steroids ever justified to treat severe bronchopulmonary dysplasia? Arch. Dis. Child. Fetal Neonatal Ed., September 1, 2007; 92(5): F334 - F337. [Full Text] [PDF]
|
|
|
|
|
|
E. D. Bruder, P. C. Lee, and H. Raff Dexamethasone treatment in the newborn rat: fatty acid profiling of lung, brain, and serum lipids J Appl Physiol, March 1, 2005; 98(3): 981 - 990. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. R. Neal Jr., G. Weidemann, M. Kabbaj, and D. M. Vazquez Effect of neonatal dexamethasone exposure on growth and neurological development in the adult rat Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2004; 287(2): R375 - R385. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. He, A. Varma, L. A. Weissfeld, and S. U. Devaskar Postnatal glucocorticoid exposure alters the adult phenotype Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2004; 287(1): R198 - R208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O Baud Postnatal steroid treatment and brain development Arch. Dis. Child. Fetal Neonatal Ed., March 1, 2004; 89(2): F96 - F100. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
